• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Cunningham Timothy M.

    7/8/24 6:16:41 AM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNOX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Cunningham Timothy M.

    (Last) (First) (Middle)
    200 GREENHILL ROAD

    (Street)
    EASTWOOD, SOUTH AUSTRALIA C3 5063

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/01/2024
    3. Issuer Name and Ticker or Trading Symbol
    BIONOMICS LIMITED/FI [ BNOX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    There are no non-derivative or derivative securities beneficially owned.
    No securities are beneficially owned.
    /s/ Timothy M. Cunningham 07/08/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BNOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNOX

    DatePrice TargetRatingAnalyst
    9/28/2023$7.00 → $10.00Buy
    Maxim Group
    9/28/2023$8.00Neutral → Buy
    H.C. Wainwright
    1/10/2022$54.00Buy
    H.C. Wainwright
    1/10/2022$52.00Overweight
    Cantor Fitzgerald
    1/10/2022$17.00Outperform
    Evercore ISI Group
    1/10/2022$21.00Buy
    Berenberg
    More analyst ratings

    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group reiterated coverage on Bionomics Limited with a new price target

      Maxim Group reiterated coverage of Bionomics Limited with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      9/28/23 12:57:32 PM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bionomics Limited upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Bionomics Limited from Neutral to Buy and set a new price target of $8.00

      9/28/23 12:33:50 PM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Bionomics Limited with a new price target

      H.C. Wainwright initiated coverage of Bionomics Limited with a rating of Buy and set a new price target of $54.00

      1/10/22 9:48:13 AM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

      ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company) is pleased to announce that the Supreme Court of New South Wales, Australia ("Court") has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States ("Scheme"), under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme. A copy of the Court's orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following t

      12/16/24 4:05:00 PM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Results of Scheme Meeting

      ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) ("Bionomics" or the "Company") is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States. Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria"), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement. Voting Results In summary: 96%

      12/12/24 4:05:00 PM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence

      BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2 2025 ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the positive results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also presented yesterday at the 63ʳᵈ Annual Meeting of the

      12/9/24 8:00:00 AM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care